COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,358 Articles (22,803 medRxiv, 8,555 bioRxiv)

Most recent first Previous |  Page 1563: Articles 15621-15630  | Next

Short-term effects of BNT162b2 mRNA COVID-19 vaccination on physiological measures: a prospective study
Gepner, Y., Mofaz, M., Oved, S., Yechezkel, M., Constantini, K., Goldstein, N., Shmueli, E., Yamin, D.
10.1101/2021.05.06.21256587 — Posted: 2021-05-07
How can risk of COVID-19 transmission be minimised in domiciliary care for older people: development, parameterisation and initial results of a simple mathematical model
Kiss, I., Blyuss, K., Kyrychko, Y., Middleton, J., Roland, D., Bertini, L., Bogen-Johnston, L., Wood, W., Sharp, R., Forder, J., Cassell, J. A.
10.1101/2021.05.05.21256598 — Posted: 2021-05-07
Intentional and unintentional non-adherence to social distancing measures during COVID-19: A mixed-methods analysis.
Eraso, Y., Hills, S.
10.1101/2021.05.04.21256444 — Posted: 2021-05-07
Unified real-time environmental-epidemiological data for multiscale modeling of the COVID-19 pandemic
Badr, H. S., Zaitchik, B. F., Kerr, G. H., Nguyen, N.-L., Chen, Y.-T., Hinson, P., Colston, J. M., Kosek, M. N., Dong, E., Du, H., Marshall, M., Nixon, K., Mohegh, A., Goldberg, D. L., Anenberg, S. C., Gardner, L. M.
10.1101/2021.05.05.21256712 — Posted: 2021-05-07
Computing a Lower Bound for the Total Size of the COVID-19 Infected Population Iceberg Using the General Age-Group Distribution
Shahar, Y., Mokryn, O.
10.1101/2021.05.04.21256588 — Posted: 2021-05-07
Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicity
Olmedillas, E., Mann, C. J., Peng, W., Wang, Y.-T., Diaz Avalos, R., Bedinger, D., Valentine, K., Shafee, N., Schendel, S. L., Yuan, M., Lang, G., Rouet, R., Christ, D., Jiang, W., Wilson, I. A., Germann, T., Shresta, S., Snijder, J., Ollmann Saphire, E.
10.1101/2021.05.06.441046 — Posted: 2021-05-06
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells
Mahoney, M., Damalanka, V. C., Tartell, M., Chung, D. H., Lourenco, A. L., Pwee, D., Mayer Bridwell, A. E., Hoffmann, M., Voss, J., Karmakar, P., Azouz, N. P., Klinger, A. M., Rothlauf, P. W., Thompson, C. E., Lee, M., Klampfer, L., Stallings, C., Rothenberg, M. E., Pöhlmann, S., Whelan, S. P. J., O'Donoghue, A. J., Craik, C. S., Janetka, J. W.
10.1101/2021.05.06.442935 — Posted: 2021-05-06
Diversity and selection of SARS-CoV-2 minority variants in the early New York City outbreak
Roder, A., Khalfan, M., Johnson, K. E., Ruchnewitz, D., Knoll, M., Banakis, S., Wang, W., Samanovic, M. I., Mulligan, M. J., Gresham, D., Laessig, M., Luksza, M., Ghedin, E.
10.1101/2021.05.05.442873 — Posted: 2021-05-06
The Effect of Minnelide against SARS-CoV-2 in a Murine Model
Caballero Van Dyke, M. C., Mead, H. L., Bryant, M., Laux, K. L., Kollath, D. R., Coyne, V. K., Miller, K. J., Stone, N. E., Jaramillo, S. A., Keim, P., Milikowski, C., Gupta, V. K., Vickers, S. M., Saluja, A., Velagapudi, M. R., Barker, B. M.
10.1101/2021.05.05.442875 — Posted: 2021-05-06
Identification of DAXX As A Restriction Factor Of SARS-CoV-2 Through A CRISPR/Cas9 Screen
Mac Kain, A., Maarifi, G., Aicher, S.-M., Arhel, N., Baidaliuk, A., Vallet, T., Tran, Q. D., Hardy, A., Chazal, M., Porrot, F., Ohainle, M., Carlson-Stevermer, J., Oki, J., Holden, K., Simon-Loriere, E., Bruel, T., Schwartz, O., Jouvenet, N., Nisole, S., Vignuzzi, M., Roesch, F.
10.1101/2021.05.06.442916 — Posted: 2021-05-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).